MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • 2025 International Congress

    Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial

    J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Martins, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

    Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…
  • 2025 International Congress

    Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson’s disease

    S. Isaacson, F. Amjad, S. Thakkar, D. Martins, H. Brigas, G. Banisadr, S. Fisher (Boca Raton, USA)

    Objective: To compare the clinical efficacy of two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: OPC and ENT are used as adjunctive therapy…
  • 2024 International Congress

    Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)

    G. Cordeiro, I. Peixoto, H. Gama, L. Magalhães, J. Moreira, J-F. Rocha, J. Holenz (Trofa, Portugal)

    Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…
  • 2024 International Congress

    Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.

    L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…
  • 2024 International Congress

    Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage

    D. Kremens, F. Amjad, S. Thakkar, B. Naderi, D. Martins, J. Rocha, G. Banisadr, S. Fisher (Wynnewood, USA)

    Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…
  • 2023 International Congress

    Adverse Events of Opicapone Adjunctive Therapy in 60 Consecutive Patients

    T. Bo, Y. Hashimoto, T. Ichikawa (Saitama, Japan)

    Objective: This study aimed to investigate the risk of adverse events (AEs) when opicapone (OPC) was added as adjunctive therapy to L-dopa administration. Background: Levodopa…
  • 2023 International Congress

    Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson’s

    G. Harrison-Jones, L. Marston, F. Morgante, K R. Chaudhuri, G. Castilla-Fernández, V. Di Foggia (Windsor, United Kingdom)

    Objective: In this retrospective cohort study, we assessed healthcare resource utilisation (HCRU) outcomes in People with Parkinson’s (PwP) naïve to Catechol-O-methyl transferase (COMT) inhibition via…
  • 2023 International Congress

    Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study

    V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

    Objective: Objectives of this study were to evaluate changes in medication, adverse events and early discontinuations of levodopa-entacapone-carbidopa-intestinal-gel (LECIG) treatment in advanced Parkinson’s disease (PD).…
  • 2023 International Congress

    Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This exploratory trial aims to compare treatment outcomes of adding one daily dose of opicapone (OPC) 50 mg versus an additional dose of levodopa…
  • 2023 International Congress

    Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study

    P. Lorenzo-Barreto, I. Pareés, P. Pérez-Torre, S. Fanjul, JL. López-Sendón, F. Pérez-Trapote, A. Sáez-Marín, E. Stiauren-Fernández, á. Patiño-Patón, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

    Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley